Insights into the future of first-line advanced hepatocellular carcinoma treatment

被引：0
|
作者：
Wong, Jeffrey Sum Lung [1 ]
Wong, Carmen Chak-Lui [2 ]
Sun, Frances Sze Kei [1 ]
Yau, Thomas [1 ,3 ]
机构：
[1] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Peoples R China
[3] Univ Hong Kong, Ctr Canc Med, Hong Kong, Peoples R China
来源：
LANCET ONCOLOGY | 2025年 / 26卷 / 02期
关键词：
ATEZOLIZUMAB; BEVACIZUMAB;
D O I：
10.1016/S1470-2045(24)00728-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：152 / 153
页数：2
相关论文
共 50 条
  • [41] An Indirect Treatment Comparison of Lenvatinib for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma
    Ndirangu, Kerigo
    Paine, Abby
    Pilkington, Hollie
    Trueman, David
    ADVANCES IN THERAPY, 2025, 42 (02) : 977 - 994
  • [42] Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma
    Wang, Xinrui
    Huang, Jihan
    Liu, Yixiao
    Wu, Lijuan
    Cai, Ruifen
    Zheng, Qingshan
    Li, Lujin
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 81 (03) : 383 - 393
  • [43] Advanced hepatocellular Carcinoma Atezolizumab plus Bevacizumab - new First-Line Therapy Standard
    Vetter, Christine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 429 - 429
  • [44] Molecular predictors of response to first-line systemic therapies in advanced hepatocellular carcinoma.
    Chang, Jeremy
    Conner, Elizabeth
    Fowler, Kathryn J.
    Tamayo, Pablo
    Burgoyne, Adam
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 534 - 534
  • [45] Advanced hepatocellular Carcinoma Atezolizumab and Bevacizumab Combination - New Standard First-Line Therapy
    Vetter, Christine
    VISCERAL MEDICINE, 2021, 37 (04) : 323 - 323
  • [46] A NETWORK META-ANALYSIS OF FIRST-LINE SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA
    Singh, B.
    Sharma, A.
    Rai, P.
    Kaur, G.
    Pandey, S.
    VALUE IN HEALTH, 2023, 26 (06) : S26 - S26
  • [47] Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
    Shao, Yu-Yun
    Wu, Chih-Horng
    Lu, Li-Chun
    Chan, Soa-Yu
    Ma, Yu-Yi
    Yen, Feng-Chu
    Hsu, Chih-Hung
    Cheng, Ann-Lii
    JOURNAL OF HEPATOLOGY, 2014, 60 (02) : 313 - 318
  • [48] The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (02) : 434 - 437
  • [49] Sorafenib and Lenvatinib as first-line treatment of hepatocellular carcinoma: A still controversial comparison
    Beenet, Linda
    LIVER INTERNATIONAL, 2021, 41 (06) : 1432 - 1432
  • [50] The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
    Chan, Landon L.
    Chan, Stephen L.
    CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 (04) : 909 - 923
12345